Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 18/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14558048 | 0.87 | ITGB1 (0.41) | HCRTR2ITGB1ITGA4 | |
| SCHEMBL2465396 | 0.82 | HSD17B10 (0.54) | HCRTR2ITGB1ITGA4SMN1; SMN2 | |
| SCHEMBL27010064 | 0.79 | POLB (0.41) | HCRTR2 | |
| SCHEMBL21522575 | 0.78 | ALDH1A1 (0.44) | HCRTR2SMN1; SMN2 | |
| SCHEMBL14569592 | 0.77 | ITGB1 (0.52) | ITGB1ITGA4 | |
| SCHEMBL10272737 | 0.77 | ROCK2 (0.46) | — | |
| SCHEMBL13662567 | 0.77 | ROCK2 (0.46) | — | |
| SCHEMBL14569751 | 0.75 | DPP4 (0.43) | SMN1; SMN2 | |
| SCHEMBL14569684 | 0.75 | ITGB1 (0.43) | HCRTR2ITGB1ITGA4SMN1; SMN2 | |
| SCHEMBL22692664 | 0.74 | HCRTR2 (0.46) | HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | HCRTR2 4577/4885ITGB1 8/4885ITGA4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.